These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 18001838)

  • 1. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
    Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
    Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Individualized pharmacotherapy based on cytochrome P-450 (CYP) genotyping].
    Johansen PW; Bergan S; Rootwelt H; Kvittingen EA; Rugstad HE
    Tidsskr Nor Laegeforen; 2002 Nov; 122(29):2781-3. PubMed ID: 12523145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 pharmacogenetics and cancer.
    Rodriguez-Antona C; Ingelman-Sundberg M
    Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
    Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
    Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.
    Murray M
    J Pharm Pharmacol; 2006 Jul; 58(7):871-85. PubMed ID: 16805946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism and toxicology--with emphasis on cytochrome p450.
    Johansson I; Ingelman-Sundberg M
    Toxicol Sci; 2011 Mar; 120(1):1-13. PubMed ID: 21149643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human genome project and novel aspects of cytochrome P450 research.
    Ingelman-Sundberg M
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):52-6. PubMed ID: 15993453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP450 pharmacogenetics for personalizing cancer therapy.
    van Schaik RH
    Drug Resist Updat; 2008 Jun; 11(3):77-98. PubMed ID: 18486526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
    Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
    Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of the molecular mechanism of human cytochrome P450 and genetic polymorphism of drug oxidative metabolizing enzyme].
    Zhao L; Lou YQ
    Sheng Li Ke Xue Jin Zhan; 1997 Jan; 28(1):35-40. PubMed ID: 10921075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic strategies for the personalization of antipsychotic treatment.
    Kerwin RW; Mancama DT; Arranz MJ
    Expert Rev Mol Diagn; 2001 Sep; 1(3):275-80. PubMed ID: 11901832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized drug therapy.
    Daly AK
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):29-36. PubMed ID: 17265738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the genetic causes of inter-patient variability. Clinical relevance with focus on cardiovascular drugs.
    Ginghină C; Stănescu R; Coman IM; Bărbari L; Popescu BA
    Rom J Intern Med; 2007; 45(4):313-9. PubMed ID: 18767405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of antipsychoatics.
    Ozaki N
    Nagoya J Med Sci; 2004 May; 67(1-2):1-7. PubMed ID: 15279062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNVs of human genes and their implication in pharmacogenetics.
    Johansson I; Ingelman-Sundberg M
    Cytogenet Genome Res; 2008; 123(1-4):195-204. PubMed ID: 19287156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphic cytochrome P450 enzymes and post-marketing drug dosage revisions: clinical relevance to dermatologic therapies.
    Saggar S; Maibach HI
    Cutan Ocul Toxicol; 2007; 26(3):171-80. PubMed ID: 17687682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.